AN2 Therapeutics Inc

Company Profile

AN2 Therapeutics Inc had its IPO on 2022-03-25 under the ticker symbol ANTX.

The company operates in the Healthcare sector and Biotechnology industry. AN2 Therapeutics Inc has a staff strength of 26 employees.

Stock update

Shares of AN2 Therapeutics Inc opened at $15.82 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $15.6 - $15.97, and closed at $15.76.

This is a +0.64% increase from the previous day's closing price.

A total volume of 24,865 shares were traded at the close of the day’s session.

In the last one week, shares of AN2 Therapeutics Inc have increased by +3.34%.

AN2 Therapeutics Inc's Key Ratios

AN2 Therapeutics Inc has a market cap of $183.16 million, indicating a price to book ratio of 1.8158 and a price to sales ratio of 0.

In the last 12-months AN2 Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures AN2 Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, AN2 Therapeutics Inc’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.

In Q3, AN2 Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

AN2 Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AN2 Therapeutics Inc’s profitability.

AN2 Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.3379. Its price to sales ratio in the trailing 12-months stood at 0.

AN2 Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$110.01 million

Total Liabilities

$4.43 million

Operating Cash Flow

$-2317000.00

Capital Expenditure

$0

Dividend Payout Ratio

0%

AN2 Therapeutics Inc ended 2025 with $110.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $110.01 million while shareholder equity stood at $105.57 million.

AN2 Therapeutics Inc ended 2025 with $0 in deferred long-term liabilities, $4.43 million in other current liabilities, in common stock, $-77881000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $28.80 million and cash and short-term investments were $104.38 million. The company’s total short-term debt was $73,000 while long-term debt stood at $0.

AN2 Therapeutics Inc’s total current assets stands at $107.30 million while long-term investments were $1.99 million and short-term investments were $75.58 million. Its net receivables were $0 compared to accounts payable of $1.44 million and inventory worth $0.

In 2025, AN2 Therapeutics Inc's operating cash flow was $-2317000.00 while its capital expenditure stood at $0.

Comparatively, AN2 Therapeutics Inc paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$15.76

52-Week High

$23.58

52-Week Low

$6.879

Analyst Target Price

$23.33

AN2 Therapeutics Inc stock is currently trading at $15.76 per share. It touched a 52-week high of $23.58 and a 52-week low of $23.58. Analysts tracking the stock have a 12-month average target price of $23.33.

Its 50-day moving average was $10.48 and 200-day moving average was $9.54 The short ratio stood at 7.74 indicating a short percent outstanding of 0%.

Around 3534.7% of the company’s stock are held by insiders while 5048% are held by institutions.